Systemic blockade of the hyaluronan receptor for endocytosis prevents lymph node metastasis of prostate cancer

Melanie A. Simpson, Janet A. Weigel, Paul H. Weigel

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Tumor progression and metastasis are promoted by the remodeling of organized tissue architecture and engagement of molecular interactions that support tumor cell passage through endothelial barriers. Prostate tumor cells that secrete and turn over excessive quantities of pericellular hyaluronan (HA) exhibit accelerated growth kinetics and spontaneous lymph node metastasis in mice. The HA receptor for endocytosis (HARE) is an endocytic clearance receptor for HA in the liver that is also highly expressed in sinusoidal endothelium of lymph nodes and bone marrow, which are frequent sites of prostate cancer metastasis. In our study, we tested the hypothesis that HARE can act as an endothelial receptor for metastatic tumor cells with pericellular HA. In an orthotopic mouse model of prostate cancer, we delivered a monoclonal antibody against HARE that specifically blocks HA binding and internalization. This treatment fully blocked the formation of metastatic tumors in lymph nodes. No effects on primary tumor growth were observed and the antibody did not induce toxic outcomes in any other tissue. Our results implicate HARE for the first time in potentiation of tumor metastasis and suggest a novel mechanism by which tumor cell-associated HA could promote tissue-specific dissemination. "Published 2012 Wiley-Liss, Inc. This article is a US Government work, and, as such, is in the public domain in the United States of America."

Original languageEnglish (US)
Pages (from-to)E836-E840
JournalInternational Journal of Cancer
Volume131
Issue number5
DOIs
StatePublished - Sep 1 2012

Fingerprint

CD44 Antigens
Endocytosis
Prostatic Neoplasms
Lymph Nodes
Neoplasm Metastasis
Hyaluronic Acid
Neoplasms
Public Sector
Poisons
Growth
Endothelium
Prostate
Bone Marrow
Monoclonal Antibodies
Antibodies

Keywords

  • HARE
  • Hyaluronan
  • Metastasis
  • Mouse orthotopic model
  • Prostate cancer
  • Stab2
  • Stabilin 2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Systemic blockade of the hyaluronan receptor for endocytosis prevents lymph node metastasis of prostate cancer. / Simpson, Melanie A.; Weigel, Janet A.; Weigel, Paul H.

In: International Journal of Cancer, Vol. 131, No. 5, 01.09.2012, p. E836-E840.

Research output: Contribution to journalArticle

Simpson, Melanie A. ; Weigel, Janet A. ; Weigel, Paul H. / Systemic blockade of the hyaluronan receptor for endocytosis prevents lymph node metastasis of prostate cancer. In: International Journal of Cancer. 2012 ; Vol. 131, No. 5. pp. E836-E840.
@article{256ec746a7184933b9f85b02a5ce7bf0,
title = "Systemic blockade of the hyaluronan receptor for endocytosis prevents lymph node metastasis of prostate cancer",
abstract = "Tumor progression and metastasis are promoted by the remodeling of organized tissue architecture and engagement of molecular interactions that support tumor cell passage through endothelial barriers. Prostate tumor cells that secrete and turn over excessive quantities of pericellular hyaluronan (HA) exhibit accelerated growth kinetics and spontaneous lymph node metastasis in mice. The HA receptor for endocytosis (HARE) is an endocytic clearance receptor for HA in the liver that is also highly expressed in sinusoidal endothelium of lymph nodes and bone marrow, which are frequent sites of prostate cancer metastasis. In our study, we tested the hypothesis that HARE can act as an endothelial receptor for metastatic tumor cells with pericellular HA. In an orthotopic mouse model of prostate cancer, we delivered a monoclonal antibody against HARE that specifically blocks HA binding and internalization. This treatment fully blocked the formation of metastatic tumors in lymph nodes. No effects on primary tumor growth were observed and the antibody did not induce toxic outcomes in any other tissue. Our results implicate HARE for the first time in potentiation of tumor metastasis and suggest a novel mechanism by which tumor cell-associated HA could promote tissue-specific dissemination. {"}Published 2012 Wiley-Liss, Inc. This article is a US Government work, and, as such, is in the public domain in the United States of America.{"}",
keywords = "HARE, Hyaluronan, Metastasis, Mouse orthotopic model, Prostate cancer, Stab2, Stabilin 2",
author = "Simpson, {Melanie A.} and Weigel, {Janet A.} and Weigel, {Paul H.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1002/ijc.27427",
language = "English (US)",
volume = "131",
pages = "E836--E840",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Systemic blockade of the hyaluronan receptor for endocytosis prevents lymph node metastasis of prostate cancer

AU - Simpson, Melanie A.

AU - Weigel, Janet A.

AU - Weigel, Paul H.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Tumor progression and metastasis are promoted by the remodeling of organized tissue architecture and engagement of molecular interactions that support tumor cell passage through endothelial barriers. Prostate tumor cells that secrete and turn over excessive quantities of pericellular hyaluronan (HA) exhibit accelerated growth kinetics and spontaneous lymph node metastasis in mice. The HA receptor for endocytosis (HARE) is an endocytic clearance receptor for HA in the liver that is also highly expressed in sinusoidal endothelium of lymph nodes and bone marrow, which are frequent sites of prostate cancer metastasis. In our study, we tested the hypothesis that HARE can act as an endothelial receptor for metastatic tumor cells with pericellular HA. In an orthotopic mouse model of prostate cancer, we delivered a monoclonal antibody against HARE that specifically blocks HA binding and internalization. This treatment fully blocked the formation of metastatic tumors in lymph nodes. No effects on primary tumor growth were observed and the antibody did not induce toxic outcomes in any other tissue. Our results implicate HARE for the first time in potentiation of tumor metastasis and suggest a novel mechanism by which tumor cell-associated HA could promote tissue-specific dissemination. "Published 2012 Wiley-Liss, Inc. This article is a US Government work, and, as such, is in the public domain in the United States of America."

AB - Tumor progression and metastasis are promoted by the remodeling of organized tissue architecture and engagement of molecular interactions that support tumor cell passage through endothelial barriers. Prostate tumor cells that secrete and turn over excessive quantities of pericellular hyaluronan (HA) exhibit accelerated growth kinetics and spontaneous lymph node metastasis in mice. The HA receptor for endocytosis (HARE) is an endocytic clearance receptor for HA in the liver that is also highly expressed in sinusoidal endothelium of lymph nodes and bone marrow, which are frequent sites of prostate cancer metastasis. In our study, we tested the hypothesis that HARE can act as an endothelial receptor for metastatic tumor cells with pericellular HA. In an orthotopic mouse model of prostate cancer, we delivered a monoclonal antibody against HARE that specifically blocks HA binding and internalization. This treatment fully blocked the formation of metastatic tumors in lymph nodes. No effects on primary tumor growth were observed and the antibody did not induce toxic outcomes in any other tissue. Our results implicate HARE for the first time in potentiation of tumor metastasis and suggest a novel mechanism by which tumor cell-associated HA could promote tissue-specific dissemination. "Published 2012 Wiley-Liss, Inc. This article is a US Government work, and, as such, is in the public domain in the United States of America."

KW - HARE

KW - Hyaluronan

KW - Metastasis

KW - Mouse orthotopic model

KW - Prostate cancer

KW - Stab2

KW - Stabilin 2

UR - http://www.scopus.com/inward/record.url?scp=84863204680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863204680&partnerID=8YFLogxK

U2 - 10.1002/ijc.27427

DO - 10.1002/ijc.27427

M3 - Article

C2 - 22234863

AN - SCOPUS:84863204680

VL - 131

SP - E836-E840

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -